you are here: HomeNewsTrendsHealth
Last Updated : Oct 29, 2020 12:44 PM IST | Source: PTI

COVID-19: Antibody response in most people strong, does not decline rapidly, study says

The research, published in the journal Science, found that this antibody response correlates with the body’s ability to neutralise the SARS-CoV-2 virus that causes COVID-19.

PTI
Representative image
Representative image

A vast majority of individuals infected with mild-to-moderate COVID 19 mount a "robust" defence via antibodies that is relatively stable for "at least five months”, according to a new study which says this immune response significantly reduces the risk of re-infection with the novel coronavirus.

The research, published in the journal Science, found that this antibody response correlates with the body’s ability to neutralise the SARS-CoV-2 virus that causes COVID-19.

"While some reports have come out saying antibodies to this virus go away quickly, we have found just the opposite — that more than 90 per cent of people who were mildly or moderately ill produce an antibody response strong enough to neutralise the virus, and the response is maintained for many months,” said Florian Krammer, a senior author of the study from The Mount Sinai Hospital in the US.

Close

"Uncovering the robustness of the antibody response to SARS-CoV-2, including its longevity and neutralising effects, is critically important to enabling us to effectively monitor seroprevalence in communities and to determining the duration and levels of antibody that protect us from reinfection,” Krammer said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

To screen individuals, the scientists used an antibody test called an enzyme-linked immunosorbent assay (ELISA) to detect the virus’ telltale spike protein which enables it to attach and gain entry into our cells.

In the study, the researchers set up antibody test results using distinct dilutions of patient serum set at 1:80, 1:160, 1:320, 1:960, or 1:2880 and higher levels (titres).

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

They explained that these scores are generated by the number of times the scientists can dilute a patient’s serum and still be able to detect the presence of antibodies.

Dilutions of 1:80 and 1:160 were categorised as low titres, containing low antibody levels, 1:320 as moderate, and 1:960 or 1:2880 categories as those with greater antibody levels.

Of the 30,082 positive samples, the study noted that 690 (2.29 percent) had a titre of 1:80; 1453 (4.83 percent) of 1:160; 6765 (22.49 percent) of 1:320; 9564 (31.79 percent) of 1:960; and 11610 (38.60 percent) of 1:2880.

Based on the findings, the scientists said a vast majority of positive individuals had moderate-to-high levels of antibodies that can neutralise the coronavirus spike protein.

The research team then assessed 120 samples of known ELISA titres ranging from "negative" to those with 1:2880 and higher levels. It found that approximately 50 percent of sera in the 1:80-1:160 titre range had neutralising activity, 90 percent in the 1:320 range could kill the virus, and all sera in the 1:960 to 1:2880 categories could block the SARS-CoV-2 virus.

It found that approximately 50 percent of sera in the 1:80-1:160 titre range had neutralising activity, 90 percent in the 1:320 range could kill the virus, and all sera in the 1:960 to 1:2880 categories could block the SARS-CoV-2 virus.

The scientists then recalled 121 recovered COVID-19 patients at a variety of titre levels for repeat antibody testing at approximately three and five months post-symptom onset.

They saw a slight drop in the antibody levels in these individuals from the first to second testing time point, and another drop for the last testing time point.

According to the researchers, this indicated that a moderate level of antibody is retained by most people five months after symptom-onset.

In the higher titre range, they said there was a slow decline of antibodies over time.

The scientists noted that there was an initial increase in titre for individuals who had originally tested as having low to moderate titre levels.

"The serum antibody titre we measured in individuals initially were likely produced by plasmablasts — cells that act as first responders to an invading virus and come together to produce initial bouts of antibodies whose strength soon wanes,” said Ania Wajnberg, another co-author of the study.

"The sustained antibody levels that we subsequently observed are likely produced by long-lived plasma cells in the bone marrow. This is similar to what we see in other viruses and likely means they are here to stay,” Wajnberg said.

According to the scientists, the vast majority of individuals with antibody titres of 320 or higher showed neutralising activity in their serum that are stable over a period of at least three months with only modest declines at the five-month time point.

Although this cannot provide conclusive evidence that these antibody responses protect from re-infection, the researchers believe the antibodies could decrease the odds of getting reinfected, and may attenuate disease in the case of breakthrough infection.

Follow our full coverage of the coronavirus pandemic here.
First Published on Oct 29, 2020 12:44 pm
Sections